FindTrial
Sign In

Polatuzumab

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Lazaros Lekakis, Jennifer Crombie, MD, Memorial Sloan Kettering Cancer Center

Conditions

Aggressive Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B-Cell LymphomaHigh Grade B Cell LymphomaLymphomaLymphoma, Large B-Cell, DiffuseNon-Hodgkin Lymphoma

Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Active, not recruitingNCT04739813
National Cancer Institute (NCI)Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Lymphoma +1
Start: 2021-07-09End: 2031-06-18Updated: 2026-06-01

Phase 2

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
RecruitingNCT05260957
Lazaros LekakisAggressive Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Start: 2022-12-14End: 2028-12-31Target: 22Updated: 2025-12-31
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
RecruitingNCT05800366
Jennifer Crombie, MDLymphoma, Lymphoma, Large B-Cell, Diffuse
Start: 2023-04-06End: 2029-09-15Target: 41Updated: 2026-03-05
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RecruitingNCT06765317
Memorial Sloan Kettering Cancer CenterDiffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Start: 2025-01-16End: 2028-01-01Target: 42Updated: 2026-07-22

Related Papers

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma
Blood2025-11-03
Optimizing frontline therapy for diffuse large B cell lymphoma (DLBCL) in older adults: A glofitamab-based, response-adapted, window-style study (GLORY).
Journal of Clinical Oncology2025-05-28